title: Stem cell mobilization in normal donors.
abstract: We studied peripheral blood and apheresis samples from 39 consecutive normal donors who were parents or siblings of patients who received matched or mismatched bone marrow transplants using a combination of rhG-CSF-mobilized peripheral blood stem cells (PBSCs) and bone marrow (BM). BM was harvested from donors 1-7 days before starting rhG-CSF treatment: 12 micrograms/kg/day rhG-CSF was administered by continuous s.c. infusion for 4-7 days. Peripheral blood progenitor cells were harvested by leukapheresis using an automated continuous-flow blood cell separator, beginning on day 4 of rhG/CSF, for 1-4 consecutive days. Peak peripheral blood CD34+ cell and CFU-GM levels were reached simultaneously on day 5 or 6 of rhG-CSF administration. Median peak levels were 1.65% for CD34+ cells (range 0.34%-4.7%) and 142 CFU-GM/10(5) plated cells (range 16-700). The greatest numbers of CD34+ cells and CFU-GM, expressed per liter of blood volume processed, were harvested during the second and third leukapheresis: CD34+ cells 37.77 +/- 25.48 x 10(6) and CFU-GM 3.32 +/- 2.51 x 10(6) during the second leukapheresis, and CD34+ cells 37.01 +/- 16.33 x 10(6) and CFU-GM 3.82 +/- 4.36 x 10(6) during the third. The number of CD34+ cells and CFU-GM did not correlate with the sex, age, or body weight of the donors. This study indicates that this protocol for administration of rhG-CSF mobilizes large numbers of hematopoietic progenitor cells into the peripheral blood and that bone marrow harvesting before G-CSF administration does not impair stem cell mobilization.
authors.affiliation: Department of Clinical Medicine, Pathology, and Pharmacology, Haematology, University of Perugia, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Tabilio
authors.forename: F
authors.initials: F
authors.lastname: Falzetti
authors.forename: C
authors.initials: C
authors.lastname: Giannoni
authors.forename: F
authors.initials: F
authors.lastname: Aversa
authors.forename: M P
authors.initials: MP
authors.lastname: Martelli
authors.forename: M
authors.initials: M
authors.lastname: Rossetti
authors.forename: P
authors.initials: P
authors.lastname: Caputo
authors.forename: F
authors.initials: F
authors.lastname: Chionne
authors.forename: C
authors.initials: C
authors.lastname: Gambelunghe
authors.forename: M F
authors.initials: MF
authors.lastname: Martelli
mesh_terms: D000328:Adult; D000368:Aged; D001854:Bone Marrow Cells; D002465:Cell Movement; D002469:Cell Separation / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000494:pharmacology; D006098:Granulocytes / Q000166:cytology; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006801:Humans; D016130:Immunophenotyping; D007937:Leukapheresis; D007963:Leukocytes, Mononuclear / Q000166:cytology; D008264:Macrophages / Q000166:cytology; D008297:Male; D008875:Middle Aged; D014019:Tissue Donors
chemical_list: D016179:Granulocyte Colony-Stimulating Factor